Research-grade peptides are remarkable molecules — short chains of amino acids that can be synthesized, lyophilized, and shipped halfway around the world while retaining biological activity. But they are not indestructible. Peptide stability depends on storage conditions, chemistry, and handling, and understanding the factors at play is essential for maintaining lot-to-lot consistency and avoiding wasted experiments.
The three dimensions of peptide stability
Peptide degradation generally proceeds through three main pathways:
- Hydrolysis: cleavage of peptide bonds by water, accelerated by acidic or alkaline conditions and by temperature. Hydrolysis is irreversible and produces shorter peptide fragments.
- Oxidation: reaction with oxygen to form oxidised species. Methionine, tryptophan, and cysteine residues are particularly susceptible. Oxidation is accelerated by light, heat, and trace metals.
- Aggregation: peptides clustering into multimers, often driven by the air-water interface (in reconstituted solution) or by improper handling. Aggregation can be reversible or irreversible depending on the chemistry.
- Carpenter, J. F., Pikal, M. J., Chang, B. S., Randolph, T. W. (1997). Rational design of stable lyophilized protein formulations. Pharmaceutical Research, 14(8), 969-975. DOI: 10.1023/A:1012180707283.
Additionally, specific peptides have unique degradation pathways: lipidated peptides can lose their lipid modification; copper-coordinated peptides can lose copper; cyclic peptides can ring-open; disulfide-containing peptides can scramble.
Temperature: the dominant variable
Every 10 °C increase in storage temperature roughly doubles the rate of chemical degradation (Q10 ≈ 2). This rule of thumb explains why peptide storage temperature matters so much:
| Storage temperature | Typical lyophilized shelf life | Typical reconstituted shelf life |
|---|---|---|
| Room temperature (20–25 °C) | 1–3 months | 1–3 days |
| 2–8 °C (refrigerator) | 6–18 months | 14–28 days |
| −20 °C (freezer) | 2–5 years | 3–6 months (avoid freeze-thaw) |
| −80 °C (ultralow) | 5+ years | 1+ year (avoid freeze-thaw) |
These are rough guides; specific peptides may exceed or fall short of these typical durations. Always refer to the supplier’s storage recommendations for the particular molecule.
Humidity
Lyophilized peptides absorb moisture from ambient air. Even small amounts of absorbed water dramatically accelerate hydrolysis. This is why proper packaging — sealed vials with rubber stoppers and aluminium crimps — is critical, and why opening and re-closing lyophilized vials repeatedly is discouraged.
Best practice: when the vial is opened for reconstitution, the entire contents should be reconstituted at once. Storing a partially-reconstituted lyophilized vial is poor practice and accelerates degradation of the unreconstituted material.
Light exposure
UV and visible light can drive oxidation reactions, particularly in peptides containing aromatic residues (tryptophan, tyrosine, phenylalanine) or photosensitive copper coordination (GHK-Cu, AHK-Cu). Light-protective storage — amber vials, or storage in original packaging in a dark refrigerator or freezer — is recommended for all research peptides.
Freeze-thaw cycles
Each freeze-thaw cycle of a reconstituted peptide solution causes some loss to aggregation. The ice-water interface during freezing concentrates the peptide and can drive irreversible association. For reconstituted solutions stored frozen, aliquot to single-use volumes at the time of reconstitution so each aliquot is thawed once.
Peptide-specific stability considerations
Methionine-containing peptides (BPC-157, many GHRH analogues): susceptible to oxidation. Use BAC water or SWFI with minimal headspace; consider adding 0.01% (w/v) methionine as a sacrificial antioxidant in long-term reconstituted storage.
Cysteine-containing peptides (insulin-like peptides, IGF-1 LR3, some growth factor analogues): susceptible to disulfide scrambling. Store at low temperature and minimise pH excursions.
Lipidated peptides (tirzepatide, semaglutide analogues, tesamorelin): the lipid modification can be hydrolysed by long storage in aqueous solution. Reconstitute fresh frequently; use BAC water cautiously due to potential foaming.
Copper-coordinated peptides (GHK-Cu, AHK-Cu): the copper coordination is sensitive to pH and chelating agents. Store at neutral pH; avoid EDTA and other chelators in formulations.
NAD+ and related cofactors: particularly unstable in solution; the dihydronicotinamide and adenine moieties are sensitive to oxidation, light, and pH. Use within 7 days of reconstitution and protect from light.
Stability programs at the supplier
A serious supplier conducts stability programs to confirm that storage recommendations are realistic. These programs:
- Place vials of representative lots in controlled storage conditions (25 °C/60% RH, 5 °C, −20 °C);
- Sample at periodic timepoints (e.g. 0, 1, 3, 6, 12, 24 months);
- Re-assay each timepoint via HPLC and MS;
- Report any loss of purity or appearance of degradation products.
The conclusions inform the labelled expiration date. Suppliers without stability data typically use conservative expiration dates (1–2 years from lot release) as a default.
Recommended storage routine
For most research-grade peptides:
- Receive lyophilized vials; transfer to 2–8 °C or −20 °C immediately upon arrival;
- Reconstitute as needed using BAC water;
- Store reconstituted solution at 2–8 °C in the original vial;
- Use within 14–28 days (28 days for BAC water; less for sensitive peptides);
- For long-term storage of reconstituted material, aliquot and freeze at −20 °C or −80 °C; thaw once per aliquot.
References & further reading
- Manning, M. C., Chou, D. K., Murphy, B. M., Payne, R. W., Katayama, D. S. (2010). Stability of protein pharmaceuticals: an update. Pharmaceutical Research, 27(4), 544–575. DOI: 10.1007/s11095-009-0045-6.
- ICH Q1A(R2) — Stability Testing of New Drug Substances and Products. International Council for Harmonisation.
- Wang, W. (1999). Instability, stabilization, and formulation of liquid protein pharmaceuticals. International Journal of Pharmaceutics, 185(2), 129–188.
- Mahler, H.-C., Friess, W., Grauschopf, U., Kiese, S. (2009). Protein aggregation: pathways, induction factors and analysis. Journal of Pharmaceutical Sciences, 98(9), 2909-2934. DOI: 10.1002/jps.21566.
- Wang, W., Singh, S., Zeng, D. L., King, K., Nema, S. (2007). Antibody structure, instability, and formulation. Journal of Pharmaceutical Sciences, 96(1), 1-26. DOI: 10.1002/jps.20727.
- Cleland, J. L., Powell, M. F., Shire, S. J. (1993). The development of stable protein formulations. Critical Reviews in Therapeutic Drug Carrier Systems, 10(4), 307-377.
- Roy, I., Gupta, M. N. (2004). Freeze-drying of proteins: some emerging concerns. Biotechnology and Applied Biochemistry, 39(2), 165-177. DOI: 10.1042/BA20030133.
- Townsend, M. W., DeLuca, P. P. (1990). Stability of ribonuclease A in solution and the freeze-dried state. Journal of Pharmaceutical Sciences, 79(12), 1083-1086. DOI: 10.1002/jps.2600791209.